CA1231894A - Procede de production d'hydrochlorure d'amosulalol a action prolongee - Google Patents

Procede de production d'hydrochlorure d'amosulalol a action prolongee

Info

Publication number: CA1231894A
Authority: CA; Canada
Prior art keywords: amosulalol hydrochloride; entero; formulation; soluble material; amosulalol
Prior art date: 1983-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000462077A

Other languages

English (en)

Inventor

Takashi Sonobe

Hiroshi Sugiura

Tomoh Itoh

Masayoshi Aruga

Hiroitsu Kawata

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yamanouchi Pharmaceutical Co Ltd

Original Assignee

Yamanouchi Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-01-21

Filing date

1984-08-29

Publication date

1988-01-26

1983-01-21 Priority claimed from JP58008619A external-priority patent/JPS58126387A/ja

1984-08-29 Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd

1988-01-26 Application granted granted Critical

1988-01-26 Publication of CA1231894A publication Critical patent/CA1231894A/fr

Status Expired legal-status Critical Current

Links

LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 title claims abstract description 49
229950010351 amosulalol Drugs 0.000 title claims abstract description 49
239000000203 mixture Substances 0.000 title claims abstract description 49
238000009472 formulation Methods 0.000 title claims abstract description 37
238000000034 method Methods 0.000 title claims description 13
239000002195 soluble material Substances 0.000 claims abstract description 20
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
229920001577 copolymer Polymers 0.000 claims description 11
239000008187 granular material Substances 0.000 claims description 11
150000007524 organic acids Chemical class 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
239000011369 resultant mixture Substances 0.000 claims description 7
239000011230 binding agent Substances 0.000 claims description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
239000011975 tartaric acid Substances 0.000 claims description 3
235000002906 tartaric acid Nutrition 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
230000001800 adrenalinergic effect Effects 0.000 abstract description 4
239000002220 antihypertensive agent Substances 0.000 abstract description 3
238000004519 manufacturing process Methods 0.000 abstract 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 5
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 4
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
229920003145 methacrylic acid copolymer Polymers 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
229920003139 Eudragit® L 100 Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
-1 2-methoxyphenoxy Chemical group 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
229920003141 Eudragit® S 100 Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

CA000462077A 1983-01-21 1984-08-29 Procede de production d'hydrochlorure d'amosulalol a action prolongee Expired CA1231894A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP58008619A JPS58126387A (ja)	1982-01-22	1983-01-21	炭水化物材料およびクラフトパルプの製造方法
JP160086/1983		1983-08-31

Publications (1)

Publication Number	Publication Date
CA1231894A true CA1231894A (fr)	1988-01-26

Family

ID=11697955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000462077A Expired CA1231894A (fr)	1983-01-21	1984-08-29	Procede de production d'hydrochlorure d'amosulalol a action prolongee

Country Status (1)

Country	Link
CA (1)	CA1231894A (fr)

1984
- 1984-08-29 CA CA000462077A patent/CA1231894A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2005-01-26	MKEX	Expiry

Publication	Publication Date	Title
US4765988A (en)	1988-08-23	Amosulalol hydrochloride long acting formulations
KR0143424B1 (ko)	1998-07-15	유핵 과립 및 그의 제조방법
US4309404A (en)	1982-01-05	Sustained release pharmaceutical compositions
CA1147650A (fr)	1983-06-07	Composes pharmaceutiques a liberation continue
JP2916152B2 (ja)	1999-07-05	薬物放出速度調節型製剤
JP2514078B2 (ja)	1996-07-10	圧縮成型製剤
US20060177502A1 (en)	2006-08-10	Sustained release pharmaceutical formulations
IL147212A (en)	2007-05-15	Process to create coated kernels with camouflaged flavor
JPH0733330B2 (ja)	1995-04-12	弾性被膜を有する安定な固形調剤及びその製造方法
US6048547A (en)	2000-04-11	Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
CZ73298A3 (cs)	1999-03-17	Farmaceutická dávkovací forma pro podávání do gastrointestinálního traktu pacienta obsahující darifenacin a způsob její výroby
WO1999016448A1 (fr)	1999-04-08	Comprime de theophylline a liberation prolongee
MXPA06009889A (es)	2007-11-20	Composicion farmaceutica que comprende pimobendano.
EP0571973A2 (fr)	1993-12-01	Comprimé au valproate de sodium à libération lente
KR102419638B1 (ko)	2022-07-12	함량 균일성이 개선된 탐수로신 염산염 함유 서방성 펠렛을 포함하는 경구용 약제학적 제제
WO1997033574A1 (fr)	1997-09-18	Comprimes a liberation prolongee a base de valproate metallique
JPH0819003B2 (ja)	1996-02-28	有核顆粒およびその製造法
EP1178780A1 (fr)	2002-02-13	Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
JP2002154948A (ja)	2002-05-28	崩壊性に優れた錠剤
CN101410091A (zh)	2009-04-15	用于持续释放格列吡嗪的药物递送系统
US20060039997A1 (en)	2006-02-23	Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
JPH04234812A (ja)	1992-08-24	持続性製剤用顆粒
CA1231894A (fr)	1988-01-26	Procede de production d'hydrochlorure d'amosulalol a action prolongee
JPH0920663A (ja)	1997-01-21	イブジラストを含有する徐放性細粒剤およびその製法
US5492700A (en)	1996-02-20	Process and composition for the development of controlled release gemfibrozil dosage form